Navigation Links
Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
Date:12/2/2008

Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints. HZT 501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, demonstrated a statistically significant reduction in the incidence of non-steroidal anti-inflammatory drug (NSAID)-induced upper gastrointestinal (gastric and/or duodenal) ulcers in patients with mild-to-moderate pain when compared to ibuprofen alone.

NSAIDs such as ibuprofen are among the most widely used drugs in the world. However, NSAIDs are associated with a range of adverse side effects, which primarily affect the gastrointestinal (GI) tract. Up to 30 percent of patients taking NSAIDs experience gastrointestinal ulcers and a greater percent suffer from upper GI symptoms (i.e., dyspepsia, heartburn).

"NSAIDs, while highly effective in treating pain and inflammation, often lead to serious safety concerns, including significant gastrointestinal damage," said Timothy P. Walbert, president and chief executive officer, Horizon Therapeutics. "We are committed to bringing this much needed treatment to physicians and patients as quickly as possible and plan on submitting these strong HZT 501 Phase 3 results to U.S. and European regulatory authorities in 2009."

REDUCE-1 and REDUCE-2 Trial Design and Results

The Registration Endoscopic Study to Determine Ulcer Formation of HZT 501 Compared to Ibuprofen: Efficacy and Safety Study (REDUCE 1 and REDUCE 2) were two randomized, double-blind, controlled trials that enrolled more than 1,500 patients in the United States. The primary efficacy objective of REDUCE-1 was to evaluate HZT 501 in reducing the proportion of patients who develop endoscopically diagnosed gastric ulcers during the 24-week treatment period, as compared to ibuprofen, in patients at risk for NSAID-ind
'/>"/>

Contact: Geoff Curtis
gcurtis@wcpglobal.com
312-646-6298
WeissComm Partners
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Push-Ups: Its Horizontal Jogging
2. United Healthcare Workers Win New Contract with Horizon West
3. Bright Horizons Founders Receive Corporate Partner Award from Ackerman Institute
4. Bright Horizons Congratulates 76 Clients Named to Working Mothers 100 Best
5. U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes
6. PFCD Experts Cite Health Care as Next Financial Casualty on Horizon
7. NJHA: Public Deserves Full Disclosure of Horizon Conversion Plan
8. Indonesias Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters
9. NJHA Raises Questions Regarding Horizons Proposal to Convert to For-Profit Health Insurer
10. Horizon Therapeutics Names Timothy P. Walbert as President and CEO
11. RxPop.com Wins 7th Annual Horizon Interactive Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... Thousands of transvaginal mesh lawsuits ( ... number of multidistrict litigations currently underway in U.S. District ... reports. According to an Order issued on December 2, ... Status Conference in all of the proceedings on January ... to submit a proposed agenda to the Court by ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... Health plan members who individually purchase their plans ... satisfied with their health plan experience, compared with ... according to the J.D. Power and Associates 2009 ... today.(Logo: http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a )Now in its third ...
... with Allen Cardoza , Los Angeles, California, April ... 2 Our special guest this week is Dr. ... practice. Shelly has been a coach and presenter to ... as a Doctor of Psychology and a Licensed Marriage ...
... found in all living cells could serve as a ... or nicotinamide adenine dinucleotide, is a key coenzyme -- ... enzyme -- found mostly in the inner membrane of ... series of biochemical reactions that involve various enzymes to ...
... on how a small hospital improved charge capture ... day using Craneware,s Bill AnalyzerATLANTA, April 2 ... provider of financial performance solutions, announced today it ... Hospital at the annual conference of the Healthcare ...
... (formerly Diagnostic Ultrasound Corporation) an innovator in medical ... care providers, is celebrating its 25th anniversary this ... 2, 1984 founding in a modest basement workshop, ... with the company,s products now used by health ...
... is a statement from Jeff Levi, PhD, Executive Director of ... of the new report Beyond Health Care: Directions to ... Commission to Build a Healthier America:"Every American should have the ... be. And every community should be safe from threats ...
Cached Medicine News:Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 3Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 4Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 5Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 6Health News:Naturally fluorescent molecules may serve as cancer biomarker 2Health News:Naturally fluorescent molecules may serve as cancer biomarker 3Health News:Craneware and St. Joseph to Present Revenue Enhancement Success Story at HIMSS 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Celebrates 25 Years of Improving Patient Care 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Celebrates 25 Years of Improving Patient Care 3Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 2Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 3
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... the "US Self-monitoring Blood Glucose Market" report ... This market insight focuses on the ... the United States . Reimbursement analysis and ... product analyses for more than 73 SMBG meters have ...
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held medical ... has been appointed Interim Chief Executive Officer of the ... succeeds Ken Berger .  "The Board of Directors ... leading ConvaTec over the past three years," said ... Directors.  "We are confident that the company is well ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... of Novel Proteasome Inhibitor in ... Patients with Relapsed Solid Tumors, SOUTH SAN ... South Texas Accelerated Research Therapeutics (START),today announced the enrollment of ... Proteolix,s investigational drug, carfilzomib (PR-171).,START is participating in the study ...
... Protects the Ocular Surface Following Exposure to ... Dry Eye Symptoms, LAGUNA HILLS, Calif., Oct. 9 ... ALTY-0501, demonstrated statistically,significant advantages over vehicle in its ability ... Phase 2 study. The Phase 2 study utilized ...
Cached Medicine Technology:Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors 2Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors 3Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 2Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 3
Inquire...
... new QIAvac 24 Plus vacuum manifold allows processing of ... tedious loading and unloading of spin columns into and ... Plus offers: Time savings ... DNA, PCR products, and RNA Convenience ...
... Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down Evaporators. For over ten years TurboVap concentration technology has received enormous ... ... ... ...
... The UltraVac manifold is designed ... The manifold holds one deep ... Samples and buffers are drawn through ... collection plates or microplates. The ...
Medicine Products: